Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
10.90
-1.18 (-9.77%)
At close: Apr 2, 2026, 4:00 PM EDT
10.99
+0.09 (0.83%)
After-hours: Apr 2, 2026, 7:49 PM EDT
Omeros Employees
Omeros had 175 employees as of December 31, 2025. The number of employees decreased by 27 or -13.37% compared to the previous year.
Employees
175
Change (1Y)
-27
Growth (1Y)
-13.37%
Revenue / Employee
n/a
Profits / Employee
-$19,143
Market Cap
784.76M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 175 | -27 | -13.37% |
| Dec 31, 2024 | 202 | 4 | 2.02% |
| Dec 31, 2023 | 198 | 2 | 1.02% |
| Dec 31, 2022 | 196 | -17 | -7.98% |
| Dec 31, 2021 | 213 | -64 | -23.10% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,300 |
| Phathom Pharmaceuticals | 371 |
| UroGen Pharma | 291 |
| Xencor | 260 |
| MapLight Therapeutics | 133 |
| Janux Therapeutics | 109 |
| Cullinan Therapeutics | 109 |
| Annexon | 99 |
OMER News
- 1 day ago - Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial Updates - Seeking Alpha
- 3 days ago - Omeros Corporation (OMER) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results - Business Wire
- 9 days ago - Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026 - Business Wire
- 14 days ago - Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment - Business Wire
- 6 weeks ago - Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program - Business Wire
- 2 months ago - Omeros Announces First Commercial Sales of YARTEMLEA® - Business Wire
- 3 months ago - Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript - Seeking Alpha